Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Flomax®

DETROIT, July 22 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) has started shipping tamsulosin hydrochloride capsules. This product was recently approved by the US Food and Drug Administration (FDA) for Sun Pharma's Abbreviated New Drug Application (ANDA). These tamsulosin hydrochloride capsules are therapeutically equivalent to Flomax® Capsules 0.4 mg from Boehringer Ingelheim Pharmaceuticals, Inc. Tamsulosin hydrochloride capsules are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).

Flomax® is a registered trademark of Astellas Pharma Inc.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limitation, the words "believe" or "expect" and similar expressions are intended to identify forward-looking statements. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission, including Part I, Item 1A of our most recent Form 10-K, and include but are not limited to: information of a preliminary nature that may be subject to adjustment, potentially not obtaining or delay in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, development by competitors of new or superior products or less expensive products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launches, dependence on few products generating majority of sales, product liability claims for which the Company may be inadequately insured, material litigation from product recalls, the purported class action lawsuits alleging federal securities laws violations, delays in returning the Company's products to market, including loss of market share, increased reserves against the FDA-seized inventory, and other risks identified in this report and from time to time in our periodic reports and registration statements. These forward-looking statements represent our judgment as of the date of this report. We disclaim, however, any intent or obligation to update our forward-looking statements.

SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Wellbutrin SR® Extended Release Tablets
2. Caraco Pharmaceutical Laboratories, Ltd. Receives Notice Regarding NYSE Amex Continued Listing Standards
3. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Optivar®
4. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Exelon® Capsules
5. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Eloxatin(R)
6. Caraco Pharmaceutical Laboratories, Ltd. Markets Nicardipine Hydrochloride Injection
7. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Ophthalmic Solution
8. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution
9. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal Year 2010
10. Caraco Pharmaceutical Laboratories, Ltd. Closes Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro(R) (escitalopram oxalate) ANDA Patent Litigation
11. Caraco Pharmaceutical Laboratories, Ltd. Enters Into Consent Decree with FDA Providing Path to Resume Manufacturing Operations
Post Your Comments:
(Date:11/24/2015)... COMMACK , Nueva York ... Avery Biomedical Devices (ABD), fabricante del Avery Breathing ... Anders Jonzon , MD; Ph.D. como consultor ...   --> Foto - ... --> El doctor Jonzon es un ...
(Date:11/24/2015)... 2015 Sectra (STO: SECT B) ... into a multi-year agreement to deploy Breast Imaging ... provide the Breast Center a future-proof platform capable of ... SECT B) announces that Breast Center of Acadiana ... Breast Imaging PACS in its two freestanding imaging centers. This ...
(Date:11/24/2015)... and BERN, Switzerland , November 24, ... Center for Biomedical Engineering Research of the University of ... of Endocrinology, Diabetes and Clinical Nutrition of the Bern ... of an exclusive collaboration to develop a novel generation ... the personalised delivery of insulin for diabetic patients with ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... ... On November 23rd 2015 Cozy Products, a division of Bird-X Incorporated, ... explains what this means for business moving forward. , The Tri Lite heater business ... to sell personal heaters that reduce energy consumption, are economical and keep people warm ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... of music, friendships, and learning in its 65th Anniversary Brillianteen Revue, scheduled for ... , For 65 years, Brillianteen has been a treasured tradition for ...
(Date:11/25/2015)... ... 25, 2015 , ... Castlewood Treatment Center for Eating Disorders, ... as a result of the $20,000 raised at the center’s recent golf ... Club in Eureka, will help individuals who otherwise might not seek treatment for ...
(Date:11/25/2015)... ... ... An unlikely combination of recycled plastic shopping bags in ... to have a more dignified and comfortable night’s sleep. , Residents of Friendship ... bags into sleeping mats for the homeless. The project, according to Jeannette ...
(Date:11/25/2015)... ... November 25, 2015 , ... Students and parents have something ... winners of the Create Real Impact awards. California Casualty is proud to ... the tide of distracted and reckless driving, the number one killer of young drivers. ...
Breaking Medicine News(10 mins):